Scientific editorial illustration of a green tea leaf, an EGCG molecular motif and a hepatocyte safety signal separated into evidence layers
Geroprotect Blog

Geroprotect research note · Evidence review

EGCG: Green Tea’s Most Studied Catechin

Human exposure, mechanistic reach and liver-safety context—without turning green-tea evidence into a longevity claim

Abstract

Epigallocatechin gallate (EGCG) is the most intensively studied catechin in green tea. Human studies establish that it is absorbed, that food materially changes its exposure, and that concentrated preparations can produce small lipid changes in some settings. They do not establish that isolated EGCG slows human aging, prevents disease or reproduces the epidemiology of tea drinking.

Safety needs the same calibration. Serious green-tea-extract liver injury appears uncommon and idiosyncratic, but its absolute frequency cannot be calculated from selected liver-injury registries. In a one-year trial using 843 mg/day of EGCG, most adverse events were mild, while alanine aminotransferase elevations were more frequent than with placebo. The European Food Safety Authority identified a liver-enzyme signal at 800 mg/day or more and could not determine a supplemental dose without concern; 800 mg is therefore a concern point, not a safe threshold. Geroprotect Essentials II lists 240 mg per full six-tablet serving. That lower amount is relevant context, not proof of safety or efficacy for the finished formula.

01 · Identity

One catechin, several very different preparations

EGCG is (−)-epigallocatechin-3-gallate, a gallated flavan-3-ol found in Camellia sinensis. It is one member of a catechin mixture that also includes epigallocatechin, epicatechin gallate and epicatechin. Brewing method, leaf processing and product standardisation all change the resulting exposure. A cup of tea also contains water-soluble constituents that are absent from purified EGCG, while extracts can deliver a concentrated amount in a short period.

That distinction is central to interpretation. An association between green-tea drinking and an outcome cannot be assigned specifically to EGCG. Likewise, a trial of a decaffeinated catechin extract cannot be treated as a trial of every green-tea product. The most defensible claims are preparation-specific.

02 · Human exposure

Food state changes the pharmacokinetic experiment

Chow and colleagues enrolled 30 healthy adults in a crossover study of Polyphenon E, a defined decaffeinated catechin mixture containing 400, 800 or 1,200 mg of EGCG. Participants received one dose after an overnight fast and one with a light breakfast. The average peak concentration of free EGCG was more than 3.5 times higher in the fasting condition. Mild transient nausea was most common at the highest dose and when fasted.1

A separate ten-day trial randomised 36 healthy men to placebo or 200, 400 or 800 mg/day of highly purified EGCG. The short exposure was well tolerated, but pharmacokinetics became more than dose-proportional at 800 mg, consistent with saturable handling or recirculation.2 These studies show why dose, formulation, duration and food state belong in any comparison. A tolerated single dose or ten-day course cannot settle chronic safety.

03 · Human outcomes

A large literature, but no human aging endpoint

A six-week randomised crossover trial in sedentary men with overweight or obesity used a decaffeinated extract containing about 800 mg/day of total catechins. Exposure markers rose, yet blood pressure, cholesterol, triglycerides, glucose and insulin did not improve. A period-by-treatment interaction suggested less weight gain during the extract period, but the investigators correctly treated this as a finding that required confirmation.3

The much larger Minnesota Green Tea Trial randomised 1,075 postmenopausal women to placebo or an extract containing 843 mg/day of EGCG for one year. An ancillary lipid analysis found small reductions in total cholesterol, LDL cholesterol and non-HDL cholesterol. LDL changed by roughly −4.1% with extract versus +0.9% with placebo.4 These are biomarkers in a specific population at a high extract dose. They do not establish fewer cardiovascular events, longer life, or an effect at 240 mg.

Tea-drinking cohorts can add long-term context, but they remain observational and include a beverage rather than isolated EGCG. Diet, smoking, activity, socioeconomic factors and reverse causation can influence those associations. No controlled study has shown that EGCG extends human lifespan, slows a validated rate-of-aging endpoint or improves the 14 hallmarks as a system.

04 · Mechanism

Interesting molecular targets, with a cell-culture warning

EGCG has unusually specific mechanistic work for a dietary polyphenol. In cancer-cell experiments, Tachibana and colleagues identified the 67-kDa laminin receptor as a high-affinity binding partner.5 Fang and colleagues found inhibition of DNA methyltransferase activity and re-expression of methylation-silenced genes in cancer cell lines, generally at micromolar concentrations.6 Other studies report AMPK-, inflammatory- and autophagy-linked signals across cells and animals.

The important restraint is experimental chemistry. EGCG and related polyphenols can auto-oxidise in common cell-culture media and generate hydrogen peroxide. Long and colleagues showed that this artefact can account for some reported cellular effects.7 A pathway result is more persuasive when it survives appropriate catalase, media, concentration and exposure controls. Even then, a cancer cell or rodent phenotype is not a clinical outcome in a healthy person.

05 · Liver safety

A recognised signal, placed in dose and population context

In the Minnesota trial, the overall frequency of adverse events and serious adverse events was similar between groups, and events were mainly mild and transient. The important exception was liver chemistry: 6.7% of participants receiving 843 mg/day of EGCG developed an ALT elevation versus 0.7% with placebo; 1.3% had ALT-related serious adverse events.8 A subsequent analysis of participants with normal baseline liver tests found challenge–dechallenge and, in some cases, rechallenge patterns that strengthened causal attribution at this high exposure.9

EFSA concluded that supplemental intakes at or above 800 mg/day had produced statistically significant transaminase elevations in intervention trials. It could not identify an EGCG dose from green-tea extracts that would be free of concern, partly because liver injury is not a simple linear dose-response phenomenon.10 Therefore, 800 mg should not be described as an approved upper limit or a dose below which risk disappears.

The US Drug-Induced Liver Injury Network identified 40 adjudicated green-tea-associated cases among 1,414 enrolled liver-injury cases. HLA-B*35:01 was present in 72% of those 40 cases, supporting an immune-mediated susceptibility signal.11 This registry is designed to characterise liver injury, not to count every green-tea-extract user. It cannot provide the absolute incidence of injury, and the HLA result does not establish a screening programme for otherwise healthy consumers.

06 · Formula context

What 240 mg in Essentials II does—and does not—mean

A full six-tablet daily serving of Geroprotect Essentials II contains 240 mg of EGCG (Epigallocatechin Gallate). This is the labelled amount of the named ingredient, not a recommended stand-alone EGCG dose and not a claim that the body absorbs 240 mg unchanged.

The amount is below the high-dose exposure used in the Minnesota trial and below the 800 mg/day point highlighted by EFSA. Cross-study dose comparison can provide orientation, but it cannot establish safety, target engagement or efficacy of a 13-ingredient formula. No component-controlled trial has tested whether EGCG adds to, duplicates or synergises with the other Essentials II actives. No evidence supports describing the combination as a proven epigenetic, autophagy or longevity intervention.

StatementEvidence boundary
EGCG is absorbedSupported; exposure varies substantially with preparation and food state.
EGCG improves metabolic healthNot established as a general claim. Controlled results are mixed and biomarker effects are modest.
EGCG changes human epigenetic agingUnproven. DNMT evidence cited here is biochemical and cell-based.
240 mg has the same liver signal as 843 mgNot shown. The clearest trial signal used a much higher exposure; EFSA still could not define a universally safe supplemental dose.
Essentials II is clinically validatedUnproven. Ingredient evidence is not a finished-formula trial.

Questions

Frequently asked questions

Is EGCG the same as drinking green tea?

No. EGCG is one catechin in green tea. A beverage, a mixed catechin extract and purified EGCG have different compositions and exposure patterns, so evidence cannot be transferred without qualification.

Is 800 mg/day an EFSA safe limit?

No. It is the intake at and above which intervention trials showed a statistically significant liver-enzyme signal. EFSA could not identify a supplemental dose without concern. The number should be treated as a concern point, not a safe threshold.

How does the 240 mg Geroprotect amount compare?

It is substantially lower than 800–843 mg/day, where the clearest controlled liver signal appears. That comparison is useful context, but the finished formula has not undergone a dedicated liver-safety or clinical-efficacy trial.

Should the liver warning dominate the article?

No. It should be visible and accurate. Most participants in the large high-dose trial did not develop clinically important liver injury, while ALT elevations were clearly more common than with placebo. The fair conclusion is uncommon but credible risk, strongly dependent on preparation, exposure and susceptibility.

Does EGCG work synergistically with the rest of Essentials II?

That has not been tested. Shared pathway diagrams are not synergy experiments, and no component-controlled human study has evaluated the complete formula.

Sources

References

  1. Chow HHS, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clinical Cancer Research. 2005;11:4627–4633. PMID 15958649.
  2. Ullmann U, et al. Plasma-kinetic characteristics of purified and isolated green tea catechin EGCG after ten days repeated dosing in healthy volunteers. International Journal for Vitamin and Nutrition Research. 2004;74:269–278. DOI 10.1024/0300-9831.74.4.269.
  3. Brown AL, et al. Health effects of green tea catechins in overweight and obese men: a randomised controlled cross-over trial. British Journal of Nutrition. 2011;106:1880–1889. PMID 21736785.
  4. Samavat H, et al. Effects of green tea catechin extract on serum lipids in postmenopausal women: a randomized, placebo-controlled clinical trial. American Journal of Clinical Nutrition. 2016;104:1671–1682. PMCID PMC5118731.
  5. Tachibana H, et al. A receptor for green tea polyphenol EGCG. Nature Structural & Molecular Biology. 2004;11:380–381. DOI 10.1038/nsmb743.
  6. Fang MZ, et al. Tea polyphenol EGCG inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Research. 2003;63:7563–7570. PMID 14633667.
  7. Long LH, et al. Artifacts in cell culture: rapid generation of hydrogen peroxide on addition of catechins and quercetin to commonly used media. Biochemical and Biophysical Research Communications. 2000;273:50–53. DOI 10.1006/bbrc.2000.2895.
  8. Dostal AM, et al. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. Food and Chemical Toxicology. 2015;83:26–35. DOI 10.1016/j.fct.2015.05.019.
  9. Yu Z, et al. Effect of green tea supplements on liver enzyme elevation: results from a randomized intervention study in the United States. Cancer Prevention Research. 2017;10:571–579. DOI 10.1158/1940-6207.CAPR-17-0160.
  10. EFSA Panel on Food Additives and Nutrient Sources added to Food. Scientific opinion on the safety of green tea catechins. EFSA Journal. 2018;16:5239.
  11. Hoofnagle JH, et al. HLA-B*35:01 and green tea-induced liver injury. Hepatology. 2021;73:2484–2493. DOI 10.1002/hep.31538.

Quality you can check

Every badge links to the document behind it: manufacturer certificates, certificates of analysis for all 26 actives, and our own promises about the formula.

Huazhen Biotechnology (Shenzhen) holds ISO 22000:2018 certificate 015FSMS2400550 and HACCP certificate 015HACCP2400460, both valid until 2 December 2027. These are manufacturer system papers, not a product certificate. The earlier papers 150FSMS2200001 and 150HACCP2200001 ended in March 2025 and are not shown as valid. Halal certificates cover raw materials from our suppliers; Geroprotect Essentials is not registered as a halal product. Food supplement. Read the current product label before use.

Bought from Geroprotect? Leave an honest review:Review us on TrustpilotReview us on GoogleReview on Amazon.aeReviews are optional and never rewarded. More about reviews.
Scroll to Top